Skip to content

*EPILEPSY AND ANXIETY: TARGETING A VICIOUS CYCLE. Effectiveness of EMDR in targeting epilepsy-related anxiety, quality of life and subjective cognitive functioning*

*EPILEPSY AND ANXIETY: TARGETING A VICIOUS CYCLE. Effectiveness of EMDR in targeting epilepsy-related anxiety, quality of life and subjective cognitive functioning* - *EPILEPSY AND ANXIETY: TARGETING A VICIOUS CYCLE.*

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51770
Enrollment
20
Registered
2022-09-12
Start date
2022-10-04
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsie anxiety

Interventions

EMDR therapy is a standardized psychological treatment, that will be delivered by licensed and experienced therapists during weekly sessions.

Sponsors

Stichting Epilepsie Instellingen Nederland
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - diagnosis of definite epilepsy (ILAE) - HADS anxiety sub score >=8 at the following three time points: at referral to the psychology department, during the interview at the psychology department and just before start of the treatment. - epilepsy-related anxiety symptoms operationalized as having a seizure-related disaster fantasy (flashforward from the EMDR protocol) - 18 years or older

Exclusion criteria

Exclusion criteria: - The presence of psychological symptoms other than anxiety in more urgent need of treatment (e.g. suicidal intent/acts or acute psychosis) - Not able to read/write and communicate in the Dutch language - Currently receiving another form of psychological treatment - Presence of psychogenic non-epileptic seizures - Presence of neurodegenerative disorders - Estimated IQ

Design outcomes

Primary

MeasureTime frame
The main outcome measure is level of anxiety, which will be assessed by several questionnaires at three time points, i.e., before treatment, directly after treatment and 3 months after treatment, and self-reported anxiety based on the diary on a weekly basis.

Secondary

MeasureTime frame
The secondary outcome measures are quality of life, subjective cognitive complaints and seizure frequency and severity, which will be administered at three time points, i.e. before treatment, directly after treatment and 3 months after treatment, and seizure frequency in the past four weeks based on the diary on a weekly basis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)